ImmunoMet Therapeutics Appoints Vincent O’Neill Chief Medical Officer

Vincent O’Neill has been named chief medical officer of cancer drug developer ImmunoMet Therapeutics. O’Neill, a medical oncologist, most recently worked at Mirna Therapeutics where he was chief medical officer. His experience also includes positions at Genentech, Roche, GlaxoSmithKline (NYSE: [[ticker:GSK]]), Sanofi (NYSE: [[ticker:SNY]]), and Exosome Diagnostics. In a separate executive move, ImmunoMet appointed Allan Shaw to serve as chief financial officer. He was most recently CFO of Syndax Pharmaceuticals (NASDAQ: [[ticker:SNDX]]). ImmunoMet, which is based in the JLABS incubator in Houston, has advanced its lead drug IM156 into early-stage clinical studies as a potential treatment for drug-resistant cancers.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan